Kwangdong to introduce new nucleoside analog RP101

Published: 2008-10-23 06:54:00

Updated: 2008-10-23 06:54:00

Kwangdong Pharm says it has entered into an exclusive license with Germany based with respect to its lead drug candidate, RP101, for the treatment of pancreatic cancer.

The company will launch in RP101 in Korea in 2012 after completion of clinical trials and registration procedures.

RESprot...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK